Journal des complications et de la médecine du diabète

A randomised control trial of comparative efficacy of Metformin,, Pioglitazone , Rosuvastatin in metabolic profile of patients with metabolic syndrome

Abstract

Indrashis Mukerjee

Metabolic syndrome is a multifactorial heterogenous disorder resulting in a variety of clinical manifestations & considered as a leading global threat. The marked variability in the cholesterol, waist circumference , blood pressure, lipid profile & fasting glucose has been characterised as components of metabolic syndrome.The developing nations are witnessing an increased trend in metabolic syndrome incidence  than compared with global incidence. International Diabetes Federation estimated that around 25% of the world’s adult population comes under diagnostic criteria of metabolic syndrome.

Treatment of metabolic syndrome has been under debate & there is no standardized pharmacotherapy yet approved for the same.

The current study was planned to evaluate & compare various potential treatments for the patients of metabolic syndrome. A prospective , open label, parallel group & randomized control trial of 12 weeks study duration was selected in which patients were randomly assigned in 4 groups to receive diet & lifestyle modification, Metformin, Pioglitazone, Rosuvastatin.

Only Rosuvastatin brought about significant increase in serum HDL which is a major marker of cardiovascular risk. Pioglitazone & Rosuvastatin were better than Metformin & lifestyle modification in reduction of serum triglycerides. Results are encouraging & are a step forward in devicing standard pharmacotherapeutic regimes beyond the current treatment modalities.